Invitae Corp Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst : So first up, just kind of wanted to talk about oncology and coverage from private payers and also Medicare. Can you just give us an update on where you stand with CMS coverage, on some of the data that you've submitted and then also how conversations are going with private payer coverage and when we can see any needle-moving updates there?

Question: Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst : Yes, on the MRD front.

Question: Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst : Great. And then maybe shifting over to the women's health business, can you just kind of walk us through? What are you seeing from a share perspective on prenatal testing? And then shifting over to the opportunity in microdeletions, can you just kind of walk us through? What are your REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 08, 2023 / 8:30PM, NVTA.N - Q2 2023 Invitae Corp Earnings Call expectations for timing on when we could expect a potential guideline change and when that would kind of bleed through to private payer coverage as well?